60 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최한곤-
dc.date.accessioned2018-02-14T05:44:06Z-
dc.date.available2018-02-14T05:44:06Z-
dc.date.issued2015-08-
dc.identifier.citationPHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, v. 20, No. 8, Page. 949-956en_US
dc.identifier.issn1083-7450-
dc.identifier.issn1097-9867-
dc.identifier.urihttp://www.tandfonline.com/doi/abs/10.3109/10837450.2014.954723-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/37441-
dc.description.abstractThe objective of this study was to develop a novel combination product containing mosapride and probiotics for the treatment of irritable bowel syndrome. Enteric-coated hard gelatin capsules containing probiotics were prepared to protect acid-labile probiotics from the stomach by spray coating with hydroxypropylmethylcellulose phthalate, and then coated with various hydrophilic polymer solutions containing mosapride. The influence of different hydrophilic polymers on the aqueous solubility and dissolution of sparingly soluble mosapride from the capsule was investigated to select the one which imparted highest solubility to mosapride in an aqueous solution. The physicochemical properties of the hydrophilic polymer coating were assessed using SEM and DSC. In addition, the bioavailability of the mosapride-coated capsule in beagle dog was evaluated and compared to that of conventional mosapride tablet (CMT). Based on DSC studies, the mosapride in polymer coating underwent amorphization or molecular dispersion. The enteric-capsule coated with mosapride/HPMC exhibited improved solubility of mosapride at acidic pH and showed significantly improved AUC (1.5-fold) and Cmax (1.6-fold) compared to the CMT. In conclusion, drug/polymer coated enteric gelatin capsule can be an alternative technique for co-delivery of sparingly water-soluble drug and acid-labile drug for enhanced solubility and bioavailability as well as for protection from acid degradation.en_US
dc.description.sponsorshipThe authors declare that they have no conflicts of interest to disclose. This study was supported by a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013; No. HT13C0011).en_US
dc.language.isoen_USen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.subjectBioavailabilityen_US
dc.subjectirritable bowel syndromeen_US
dc.subjectmosaprideen_US
dc.subjectprobioticsen_US
dc.subjectsolubilityen_US
dc.subjectLACTIC-ACID BACTERIAen_US
dc.subjectIN-VIVO EVALUATIONen_US
dc.subjectLACTOBACILLUS-ACIDOPHILUSen_US
dc.subjectSOLID DISPERSIONen_US
dc.subjectCONTROLLED-TRIALen_US
dc.subjectKNOCKOUT MICEen_US
dc.subjectDOUBLE-BLINDen_US
dc.subjectBIFIDOBACTERIUMen_US
dc.subjectAS-4370en_US
dc.subjectANTAGONISTen_US
dc.titleDevelopment of a novel bi-coated combination capsule containing mosapride and probiotics for irritable bowel syndromeen_US
dc.typeArticleen_US
dc.relation.no8-
dc.relation.volume20-
dc.identifier.doi10.3109/10837450.2014.954723-
dc.relation.page949-956-
dc.relation.journalPHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY-
dc.contributor.googleauthorKim, Yong il-
dc.contributor.googleauthorPoudel, Bujay Kumar-
dc.contributor.googleauthorPradhan, Roshan-
dc.contributor.googleauthorChoi, Han Gon-
dc.contributor.googleauthorYong, Chul Soon-
dc.contributor.googleauthorWoo, Jong Soo-
dc.contributor.googleauthorKim, Jong Oh-
dc.relation.code2015014121-
dc.sector.campusE-
dc.sector.daehakCOLLEGE OF PHARMACY[E]-
dc.sector.departmentDEPARTMENT OF PHARMACY-
dc.identifier.pidhangon-
Appears in Collections:
COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE